Bmkvaccine Lr 143

What We Do

Virus Like Particle projects

Hypocat neutralises major cat produced human allergen (Fel d 1), 10% of people are allergic to cats. The development is a recombinant Cucumber Mosaic Virus linked to recombinant Fel d 1. It is a unique development with no competitor product in cats. Sales are forecast to be in the region of £250M pa.

Canine Atopic Dermatitis (CAD) for treatment of dogs 10% of whom suffer from this condition. The Development is recombinant Cucumber Mosaic Virus linked to a number of recombinant interlukins. The CAD market is in excess of £1Billion pa and is the biggest veterinary problem in dogs mainly treated by immunosuppressive drugs which have to be taken for life. (e.g. Zoetis -Apoquel)

Aqua vaccine VLP projects - vaccine concept being tested in fish currently.

Virus Like Particles Vaccines

VLPs are multi protein structure that mimic native viruses but lack the viral genome.

The technology is used in several licenced vaccines for example GSK’s Engerix Hepatitis B vacccine and Merck’s Gardasil Human Papilloma Virus vaccines.

The VLP monomer proteins in the Hypocat vaccine are from the Cucumber Mosaic Virus (CMV). The viral coat proteins are cloned and expressed in E.coli which self assemble into VLP’s inside the bacteria. The bacteria are lysed and the VLP are purified.

The Hypocat VLP’s are then chemically cross-linked to recombinant Fel d 1 proteins ( cat allergen antigen). 

main.css loaded.